国际PSC研究组关于磁共振成像在原发性硬化性胆管炎中应用的建议:立场声明
国际PSC研究组成员与北美和欧洲的放射科医生共同制定立场声明,针对MRI在原发性硬化性胆管炎患者诊疗中的应用、最低成像标准及未来研究方向提供指导;声明指出MRI是无创诊断PSC和检测疾病相关并发症的影像方法,定量MRI技术有潜力提供有价值的预后信息,但各机构临床应用的成像标准存在差异。
要点
- MRI是无创诊断PSC和检测疾病相关并发症的影像方法。
- 定量MRI技术有潜力提供有价值的预后信息。
- 各机构PSC患者MRI临床应用和成像标准存在差异。
核心结论
- 国际PSC研究组与北美和欧洲放射科医生共同编写立场声明,为MRI在PSC患者诊疗中的应用、最低成像标准及未来研究领域提供指导。
研究设计与样本
- 国际PSC研究组成员与北美和欧洲的放射科医生共同制定的立场声明,发表于Hepatology 2017;66:1675-1688。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
UNLABELLED: Primary sclerosing cholangitis (PSC) is a chronic cholestatic liver disorder characterized by inflammation and fibrosis of the intra- and/or extrahepatic bile ducts. Magnetic resonance imaging (MRI) is a noninvasive imaging modality that can be used to diagnose PSC and detect disease related complications. Quantitative MRI technologies also have the potential to provide valuable prognostic information. Despite the potential of this imaging technology, the clinical application of MRI in the care of PSC patients and imaging standards vary across institutions. Moreover, a unified position statement about the role of MRI in the care of PSC patients, quality imaging standards, and its potential as a research tool is lacking.
CONCLUSION: Members of the International PSC Study Group and radiologists from North America and Europe have compiled the following position statement to provide guidance regarding the application of MRI in the care of PSC patients, minimum imaging standards, and future areas of research. (Hepatology 2017;66:1675-1688).
引用
- Schramm C, Eaton J, Ringe KI, et al. Recommendations on the use of magnetic resonance imaging in PSC-A position statement from the International PSC Study Group. Hepatology. 2017. PMID: 28555945. doi:10.1002/hep.29293
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。